{"entity":{"id":"nct02097875","kind":"trial","name":"Safety Study of a Fluorescent Marker to Visualize Cancer Cells","aka":[],"tldr":"A phase 1 trial of Tozuleristide run by Blaze Bioscience Australia Pty Ltd, completed.","summary":"Safety Study of a Fluorescent Marker to Visualize Cancer Cells is a phase 1 interventional study registered as NCT02097875 by Blaze Bioscience Australia Pty Ltd, with 21 participants enrolled, started 2013-12. Conditions recorded: Skin Neoplasms. Interventions recorded: BLZ-100.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02097875","url":"https://clinicaltrials.gov/study/NCT02097875"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["blz-100"],"companies":["blaze-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02097875","phase":"1","setting":"A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer","sponsor":"Blaze Bioscience Australia Pty Ltd","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02097875/","neighbours":{"cancer":[{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"drug":[{"id":"blz-100","kind":"drug","name":"Tozuleristide","route":"/drugs/blz-100/"}],"company":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/"}]}}